Navigation Links
First-in-class treatment for acute leukemia
Date:12/8/2009

think it has the potential to make a big difference in the treatment of AML. In fact the European Medicines Agency has designated AML an orphan disease as there is a big medical need and no other treatment available." For AML treatment, the new drug is anticipated to achieve the same result as marrow bone transplantations 50-70% of patients surviving and improving.

Although there are already other therapies for chronic myeloid leukaemia, there is still a need for better treatment options. When one of the main existing treatments for CML was introduced, it quickly reached a market of over $1 billion a year. There are about the same number of patients with AML and CML in the western world, so the market for a new effective cancer treatment is very promising.

Fruitful partnership

This particularly successful EUREKA project built on the complementary skills of the small innovative and dynamic biotech company and the larger pharmaceutical company, with its technology base and experience of clinical drug development. The project was financially supportive to Innate Pharma; particularly important in the early stages by enabling investigative work that would otherwise not have been possible from the start. This generated a momentum and early progress that helped win further investment from Novo Nordisk during the collaboration, Novo Nordisk became a main investor in Innate Pharma.

The Danish company benefited through sharing Innate Pharma's early concept, and by gaining access to Innate Pharma's patents on the strategic approach to the drug design. This was critical to the project and laid the foundation for a larger series of patent applications filed by the two companies in collaboration. The French company's patent platform and technical competences were complemented by drug-discovery and clinical skills from the Danish partner.


'/>"/>

Contact: Francois Romagn
Francois.Romagne@innate-pharma.fr
33-430-303-030
EUREKA
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Nicotinic receptors may be important targets for treatment of multiple addictions
2. A new radiation therapy treatment developed for head and neck cancer patients
3. Restoring sight, advances in fertility treatments and better visibility for pilots at FIO
4. Presence of gene mutation helps guide thyroid cancer treatment
5. U of M begins nations first clinical trial using T-reg cells from cord blood in leukemia treatment
6. New genetic research into nicotine addiction shows promise for personalized treatment
7. Interleukin-8, key marker for colorectal cancer treatment
8. New class of drug offers hope to treatment-resistant AIDS patients
9. Paradigm shift in Alzheimerss research: new treatments
10. New research on structure of bones raises questions for treatment of osteoporosis
11. Major genetic breakthrough for ankylosing spondylitis brings treatment hope
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/18/2014)... 2,000 patients referred for evaluation of suspected genetic ... for 25 percent, including detection of a number ... to disease, according to a study appearing in ... to coincide with the American Society of Human ... exons or coding regions of thousands of genes ...
(Date:10/17/2014)... German . Why ... order to reproduce? And why are there two sexes anyway? ... issue of the research journal Molecular Human Reproduction ... from Bielefeld University Bielefeld has compiled this special issue on ... female to copulate with several males in quick succession – ...
(Date:10/16/2014)... Cancer constantly wages war on the human body. ... a stalemate. In pancreatic cancer, this stalemate—known as ... becoming aggressively malignant, a phenomena that is poorly ... in the laboratory of Salvatore Torquato, a Professor ... the conditions surrounding tumor dormancy and the switch ...
Breaking Biology News(10 mins):Whole-exome sequencing shows potential as diagnostic tool 2Sperm wars 2Modeling tumor dormancy 2
... Food and Drug Administration (FDA) has granted approval to ... Alza Corporation's Duragesic Patch (Fentanyl Transdermal System) used to ... be managed with alternative analgesics. When applied to the ... medication that is slowly absorbed into the body through ...
... found that introducing a growth factor protein into a mouth ... according to a new paper in the February issue of ... sizeable mouth wound, replacing a tooth takes more than simply ... to anchor the new tooth in place. Such reconstructive surgery ...
... protein called IRE1, which helps stressed-out cells make new ... believed. A new study by researchers from the University ... Institute reveals the surprising finding that this same signaling ... called B lymphocytes. , "This is a unique signaling ...
Cached Biology News:Gene therapy promising for growing tooth-supporting bone 2Gene therapy promising for growing tooth-supporting bone 3Multi-purpose protein regulates new protein synthesis and immune cell development 2Multi-purpose protein regulates new protein synthesis and immune cell development 3
(Date:10/22/2014)... VANCOUVER , Oct. 22, 2014 /PRNewswire/ - iCo ... ICOTF), today announced next steps for its Oral ... findings from its in vitro work ... therapy.  iCo now plans to complete pre clinical ... an initial Phase 1A clinical trial, utilizing approximately ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 The ... (Medication Dispensing Systems, Packaging and Labeling Systems, Table-top ... Automation) - Global Forecasts & Trends to 2019” ... and opportunities in North America, Europe, Asia-Pacific, and ... 101 market tables and 30 figures spread through ...
(Date:10/20/2014)... 20, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the ... Q3 orders to $5.8 million and provides a good start to ... North America and one in the ... projects at record levels," said Peter Bruijns , President & ... end of Q3 than they have been for any complete year ...
(Date:10/20/2014)... October 20, 2014 OncLive® ... Kimmel Cancer Center at Thomas Jefferson University has ... Through the Strategic Alliance Partnership program, the Sidney ... collaborate to raise awareness of the Center’s cutting-edge ... other projects. Clinicians and other health care professionals ...
Breaking Biology Technology:iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3
... - MacoPharma increased its forecast for P-Capt(R) filters sale in 2008;, - Use of affinity prion adsorbent for ... in excess of $25 M over the next 5 years ... - $4 M in 2008;,- 10th product approved by the FDA and or the EMEA, contributing ... growth., MONTREAL, ...
... Cholesterol Test Can Help Identify Patients At Risk of Heart ... ... Atherotech, Inc., a,cardio-diagnostic company, today announced that the largest private,insurers in ... (FEHB) Program now cover the VAP (Vertical Auto Profile),Test, the most ...
... Software Platform Further Solidifies Netsmart as Leader in Behavioral Healthcare ... ... Florida, GREAT RIVER, N.Y., Feb. 6 Netsmart Technologies, Inc.,a ... organizations, today announced it has signed a contract to,provide comprehensive licensed ...
Cached Biology Technology:ProMetic provides business update - Over $35 million worth of business secured in January 2ProMetic provides business update - Over $35 million worth of business secured in January 3ProMetic provides business update - Over $35 million worth of business secured in January 4VAP Cholesterol Test From Atherotech Covers 90 Percent of Arizona Insured 2Netsmart Technologies Extends Relationship with Manatee Glens for Enterprise Behavioral Health Software Solutions 2Netsmart Technologies Extends Relationship with Manatee Glens for Enterprise Behavioral Health Software Solutions 3
... Biosearch Technologies has been at the ... accelerate the discovery and application of ... FRET probes and primers or 100 ... applications, Biosearch can meet your most ...
Cultrex 3D Culture Matrix Rat Collagen I....
UNIVERSAL SCORECARD DNA, 1 EA. * Category: Reagents/Consumables....
Cultrex 3D Culture Matrix Laminin I....
Biology Products: